Tirzepatide działanie: what actually happens inside your body

You've started reading about tirzepatide and hit a wall of jargon

Most explanations of how tirzepatide works begin with acronyms and receptor biology and lose you within two sentences. So start here instead: your gut releases hormones when you eat. Two of the most important for appetite and blood sugar are GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both signal to the brain and pancreas that food has arrived. Tirzepatide is a synthetic molecule engineered to mimic both of them at once, binding to the GIP receptor and the GLP-1 receptor with high affinity.

Why does that matter? Because activating both pathways produces effects that activating only one cannot fully replicate. The GLP-1 receptor slows gastric emptying, which keeps food in the stomach longer and extends the feeling of fullness. It also blunts post-meal blood-sugar spikes. The GIP receptor adds to that: it enhances the insulin response, may improve how efficiently fat cells respond to hormonal signals, and appears to reinforce the appetite-suppressing effect of GLP-1 rather than opposing it. The combined result is a stronger, more sustained reduction in appetite than either pathway alone can deliver. This is the reason NICE's appraisal of tirzepatide, published as TA1026, noted that indirect comparisons from available evidence favoured tirzepatide over semaglutide, the only other licensed injectable in this class.

The medicine is delivered once weekly by subcutaneous injection, using Eli Lilly's pre-filled KwikPen. You'll find a fuller overview of the pen itself and how treatment is structured on the tirzepatide page.

What your body actually experiences week by week

The starter dose of 2.5 mg isn't a therapeutic target, its job is adjustment. Your gut and brain are being introduced to a new hormonal signal, and starting low reduces the likelihood of nausea and other gastrointestinal side effects that come with more abrupt stimulation of these pathways. Most people notice only modest appetite changes at first. That's expected.

As the prescriber increases the dose, typically in four-week steps through 5 mg, 7.5 mg, up to tirzepatide 10 mg, which you can read about on its own page, 12.5 mg and up to 15 mg depending on response and tolerability, the dual-receptor stimulation intensifies. Appetite reduction becomes more pronounced. Many people report that food feels less urgent, the mental background noise of hunger quietens noticeably. Gastric emptying slows further, which means smaller portions produce the same sense of fullness that larger ones used to.

The gastrointestinal side effects that are most common (nausea, loose stools, indigestion) tend to cluster around the first days after starting or after a dose increase, then settle. They're a direct consequence of the mechanism: slowing gastric emptying affects digestion. The NHS tirzepatide information page covers the side-effect profile clearly, including which symptoms warrant prompt medical attention.

One practical note: if you're planning a holiday or there's a long weekend coming up, order early. Our pharmacy dispatches the same working day for orders placed by 12pm Monday to Friday, but bank holidays affect that window, worth factoring in before a dose is due.

How the trial data maps onto the mechanism

The SURMOUNT-1 trial ran for 72 weeks, enrolling adults with obesity or overweight alongside at least one weight-related condition, without type 2 diabetes. Those who received tirzepatide across the full 30-week titration period and beyond lost an average of around 20–21% of their body weight at the 15 mg maintenance dose. A 2025 head-to-head study, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks in a similar population and found tirzepatide produced greater average weight reduction, the first direct comparison to confirm what indirect analyses had suggested.

These figures come from controlled trial conditions alongside dietary and lifestyle support; individual results vary and depend on the dose reached, adherence, and a person's own biology. The dual-pathway mechanism explains why the numbers are what they are, but it doesn't guarantee any particular outcome for any individual. For a broader look at how tirzepatide compares with other options, the Mounjaro or tirzepatide page addresses a question our prescribers hear often, and if you want to explore Mounjaro in detail, including its licensed indications and pen formats, that page covers the full picture alongside the two-names question. If you're curious about weight-loss treatment options more broadly, including how lifestyle support works alongside medication, that context is worth reading before a consultation.

Who the mechanism suits, and where the prescriber's role comes in

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, type 2 diabetes or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But the licensed criteria are a starting point, not the whole picture.

The mechanism doesn't work the same way in everyone. People with certain gastrointestinal conditions, a personal or family history of medullary thyroid carcinoma or MEN2, or who are pregnant, breastfeeding or trying to conceive are not suitable candidates. Women using oral contraceptives need to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's slowing of gastric emptying can reduce how much of an oral pill is absorbed. This is a detail that matters and that a prescriber will discuss with you, it's explained further in the NHS England guidance on weight-management injections.

The prescriber's role isn't just to tick eligibility boxes. They're assessing whether this specific mechanism suits your specific health picture, at what dose, and how to titrate safely. If you want to understand the upper end of the dose range, our tirzepatide L pen page explains how that format fits into treatment. You can read about the clinical team at our clinical team page or see answers to common clinical questions on the FAQs page. When you're ready to take the next step, speak to our prescribers through a free consultation, a real clinician reads your answers the same day, not a piece of software.